Moderna and Recordati are working together to create a new treatment called mRNA-3927 for propionic acidemia, a rare metabolic disorder that currently lacks effective treatments. This treatment is designed to be given through an IV and aims to help the body produce functional enzymes that are missing in people with this condition. The agreement between the two companies could be worth over $150 million. Moderna will continue to develop the treatment, and if it’s approved, Recordati will handle its global sales. Recordati will pay Moderna $50 million upfront and potentially up to $110 million more if certain milestones are reached. Rob Koremans, CEO of Recordati, expressed excitement about the partnership, highlighting the combined expertise of both companies in innovative technology and rare metabolic disorders. He also mentioned that early results from a phase I/II study of mRNA-3927 are promising. Stéphane Bancel, CEO of Moderna, also expressed pride in the partnership, noting that Recordati’s experience in rare diseases will help accelerate the benefits of mRNA-3927 upon approval. This news follows Moderna’s recent $500 million collaboration with Nanexa to advance mRNA drug delivery and medicines.